Skip to Content
MilliporeSigma
  • Improved facial nerve outcomes using an evolving treatment method for large acoustic neuromas.

Improved facial nerve outcomes using an evolving treatment method for large acoustic neuromas.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology (2013-02-28)
Ryan G Porter, Michael J LaRouere, Jack M Kartush, Dennis I Bojrab, Daniel R Pieper
ABSTRACT

To describe a successful paradigm for the treatment of large acoustic neuromas (vestibular schwannomas). Retrospective case review. Tertiary referral center. The charts of 2,875 acoustic neuroma patients at Michigan Ear Institute were reviewed to identify 153 patients who underwent surgical resection for large acoustic neuromas (>=3 cm) between 2000 and 2009. Staged surgical resection or single stage surgery with or without adjuvant stereotactic radiosurgery. Postoperative facial nerve outcomes are reported using the House-Brackmann (HB) facial nerve grading scale and compared with historical controls from a literature review. Rates of adverse outcomes are also reported. Seventy-five patients underwent staged surgical resection of their tumors, whereas 78 patients underwent either single stage surgery or surgery with subsequent stereotactic radiosurgery. Eighty-one percent of patients in the staged surgical resection group had a postoperative HB Grade I or II facial nerve function compared with 75% in the single stage surgical group. Overall, 78% of patients in the current study had HB Grade I or II after treatment compared with a mean of 53% in the literature for similar sized tumors. Our methods including the decision to use staged surgery when necessary, dissection of tumor with stimulating dissector-directed intraoperative monitoring, and use of adjuvant stereotactic radiosurgery are described. Using the described paradigm, large acoustic neuromas can be successfully treated with either staged or single-stage surgical resection with or without adjuvant radiosurgery to obtain more favorable facial nerve outcomes than historically reported controls while minimizing morbidity for the patient.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Silicone oil, viscosity 500 cSt (25 °C)
Sigma-Aldrich
Silicone oil, viscosity 30,000 cSt (25 °C)
Sigma-Aldrich
Silicone oil, viscosity 100,000 cSt (25 °C)
Sigma-Aldrich
Silicone oil, viscosity 1,000 cSt (25 °C)
Sigma-Aldrich
Silicone oil, viscosity 5 cSt (25 °C)
Sigma-Aldrich
Silicone oil, viscosity 350 cSt (25 °C)
Sigma-Aldrich
Silicone oil, viscosity 20 cSt (25 °C)
Sigma-Aldrich
Silicone oil, viscosity 10,000 cSt (25 °C)
Silicone oil, for melting point and boiling point apparatuses
Sigma-Aldrich
Silicone oil, for oil baths (from −50°C to +200°C)
Sigma-Aldrich
Silicone oil, Dow Corning 200® fluid, viscosity 60,000 cSt (25 °C)
Sigma-Aldrich
Silicone oil, viscosity 50 cSt (25 °C)
Sigma-Aldrich
Silicone oil, viscosity 10 cSt (25 °C)
Sigma-Aldrich
Silicone oil, viscosity 100 cSt (25 °C)